Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial

نویسندگان

  • Andrea Natali
  • Lorenzo Nesti
  • Iacopo Fabiani
  • Enrico Calogero
  • Vitantonio Di Bello
چکیده

BACKGROUND Asymptomatic left ventricular (LV) dysfunction is highly prevalent in type 2 diabetes patients. Unlike the other hypoglycemic drugs, SGLT2 inhibitors have shown potential benefits for reducing cardiovascular death and risk factors, aside from lowering plasma glucose levels. With this study we aim at determining whether the treatment with empagliflozin is associated with an improvement in LV functions in diabetic patients with asymptomatic LV dysfunction against Sitagliptin, which is presumably neutral on myocardial function. To determine changes in LV systolic and diastolic functions we will use speckle-tracking echocardiography, a novel sensitive, non-invasive, bedside method allowing the calculation of LV global longitudinal strain (GLS), an index of myocardial deformability, as well as 3D echocardiography, which allows a better evaluation of LV volumes and mass. METHODS The EMPA-HEART trial will be a phase III, open label, active-controlled, parallel groups, single centre, exploratory study conducted in Pisa, Italy. A cohort of 75 diabetic patients with normal LV systolic (2D-Echo EF > 50%) and renal (eGFR sec MDRD > 60 ml/min/1.73 mq) functions and no evidence of valvular and/or ischemic heart disease will be randomized to either Empagliflozin 10 mg/die or Sitagliptin 100 mg/die. The primary outcome is to detect a change in GLS from baseline to 1 and 6 months after treatment initiation. The secondary outcomes include changes from baseline to 6 months in 3-D Echocardiography EF, left atrial volume and E/E', VO2max as measured at cardiopulmonary test, cardiac autonomic function tests (R-R interval during Valsalva manoeuvre, deep-breathing, lying-to-standing), and the determination of a set of plasma biomarkers aimed at studying volume, inflammation, oxidative stress, matrix remodelling, myocyte strain and injury. DISCUSSION SGLT2 inhibitors might affect myocardial functions through mechanisms acting both directly and indirectly on the myocardium. The set of instrumental and biohumoral tests of our study might actually detect the presence and entity of empagliflozin beneficial effects on the myocardium and shed light on the mechanisms involved. Further, this study might eventually provide information to design a clinical strategy, based on echocardiography and/or biomarkers, to select the patients who might benefit more from this intervention. Trial registration EUDRACT Code 2016-0022250-10.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Empagliflozin and the Prevention of Heart€Failure

SEE PAGE 347 H eart failure develops in more than 1 in 5 patients with diabetes mellitus (DM) older than 65 years of age and augers an extremely poor prognosis, with a median survival of approximately 4 years. The landmark EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) showed that empagliflozin significantly reduced the primary composite...

متن کامل

Evaluation of the Effect of Empagliflozin Therapy on T Helper 22 Cell-Related Factors in Patients with Type 2 Diabetes Mellitus

Background and Objective:The increased response of T helper (Th) 22cells might be involved in thepathogenesis ofType 2 Diabetes Mellitus (T2DM). The present study aimed to investigate the transcription factor of Th22 cells (aryl hydrocarbon receptor [AHR]) and interleukin 22 (IL-22) in CD4+ T cells as well as the impact of oral empagliflozin treatment. The correlation between the aforementioned...

متن کامل

The Effect of Endurance and High-Intensity Interval Training on the Content MSTN and Follistatin Proteins in the Left Ventricular Tissue of The Heart of Type 1 and 2 Diabetic Rats

Background: Diabetes is an important factor in heart defects that can lead to atrophy of heart cells. Exercise can prevent the complications of diabetes by regulating cellular factors. Therefore, the aim of the present study was to evaluate the effect of endurance and high-intensity interval training on the content MSTN and Follistatin proteins in the left ventricular tissue of the heart of typ...

متن کامل

Effect of a Six-Week Endurance Exercise and Empagliflozin Consumption on Some Structural and Functional Indices of the Heart in Male Diabetic Rats

Background: The aim of this study was to evaluate the effect of eight weeks of endurance training and Empagliflozin consumption on inflammatory markers and their relationship with heart structure and function of diabetic male Rats. Methods: 40 male Wistar rats were randomly divided into five groups: healthy control, diabetic control, diabetic + empagliflozin, diabetic + endurance training and ...

متن کامل

THE EFFECT OF ENDURANCE TRAINING ON THE CONTENT MYOSTATIN AND SMAD2/3 PROTEINS IN THE LEFT VENTRICULAR TISSUE OF THE HEART MUSCLE OF TYPE 1 DIABETIC RATS

Background: The myostatin/SMAD pathway is one of the most important regulatory pathways in heart muscle cells atrophy. Diabetes can disorder this pathway. Therefore, the aim of the present study was to evaluate the effect of six weeks of endurance training on the content myostatin and SMAD2/3 proteins in the left ventricular tissue of the heart muscle of type 1 diabetic rats. Methods: In this ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 16  شماره 

صفحات  -

تاریخ انتشار 2017